Description
The 10D5 monoclonal antibody specifically recognizes Integrin alpha v beta 6 (αvβ6) that is also known as CD51/β6. This heterodimeric receptor is comprised of transmembrane type I alpha and beta chain glycoproteins that are encoded by ITGAV (integrin subunit alpha) and ITGB6 (integrin subunit beta 6), respectively. Like other integrins, αvβ6 serves as a transmembrane adhesion receptor that can tether the intracellular cytoskeleton to the extracellular matrix (ECM) by binding to R-G-D sequences of ECM protein ligands including fibronectin, vitronectin, and tenascin. Integrin αvβ6 likewise plays a key role in the activation of transforming growth factor beta-1 (TGFβ1) by its R-G-D-dependent release of TGFβ1 from regulatory Latency-associated peptide (LAP). Some viruses, such as. Coxsackieviruses and Herpes simplex virus-1 use Integrin αvβ6 as a receptor to infect cells. Integrin αvβ6 engages in bidirectional signaling, ie, outside-in and inside-out signaling, to regulate essential cellular functions. These include adhesion, migration, polarization, differentiation, and proliferation that are crucial to tissue homeostasis. Although not normally expressed on adult epithelial cells/keratinocytes, its expression is upregulated on these cells during the course of embryonic development, inflammation, tissue injury, wound healing, as well as malignant transformation. The 10D5 antibody blocks Integrin αvβ6-dependent cellular adhesion and migration and reportedly recognizes both human and mouse αvβ6 integrins. Binding of 10D5 antibody to αvβ6 is divalent-cation dependent.
BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and CompBead to ensure that BD Comp beads are appropriate for your specific cellular application. For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. Researchers should determine the optimal concentration of this reagent for their individual applications.
3. An isotype control should be used at the same concentration as the antibody of interest.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
9. BD Horizon Brilliant Ultraviolet 395 is covered by one or more of the following US patents: 8,158,444; 8,575,303; 8,354,239.
